B Paul Morgan Selected Research

Complement Factor B (Factor B)

1/2019	Complement system biomarkers in first episode psychosis.
5/2014	Complement activation in multiple sclerosis plaques: an immunohistochemical analysis.
5/2011	Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.
12/2010	The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury.
3/2009	Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B.
1/2007	Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

B Paul Morgan Research Topics

Disease

29	Inflammation (Inflammations) 01/2022 - 09/2003
14	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 03/2009
14	Infections 01/2021 - 01/2002
13	Macular Degeneration (Age-Related Maculopathy) 01/2020 - 02/2007
12	Neoplasms (Cancer) 01/2022 - 03/2004
10	Multiple Sclerosis 01/2020 - 01/2002
9	Myasthenia Gravis 01/2022 - 09/2007
7	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 01/2002
7	Atypical Hemolytic Uremic Syndrome 01/2020 - 01/2007
7	Hemolysis 12/2018 - 12/2003
5	Wounds and Injuries (Trauma) 05/2022 - 06/2011
5	Neuromyelitis Optica (Devic's Disease) 01/2022 - 06/2017
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 02/2002
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2018 - 01/2002
4	Neuroinflammatory Diseases 01/2018 - 05/2006
4	Peritonitis 01/2017 - 07/2009
4	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 05/2014 - 01/2009
3	Rheumatoid Arthritis 01/2022 - 04/2015
3	Central Nervous System Diseases (CNS Diseases) 12/2021 - 05/2014
3	COVID-19 01/2021 - 11/2020
3	Disease Progression 01/2021 - 01/2017
3	Psychotic Disorders (Schizoaffective Disorder) 01/2021 - 01/2019
3	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2020 - 12/2014
3	Dementia (Dementias) 01/2020 - 03/2009
3	Traumatic Brain Injuries (Traumatic Brain Injury) 11/2015 - 01/2009
3	Proteinuria 02/2004 - 12/2002
2	Arthritis (Polyarthritis) 01/2022 - 10/2002
2	Renal Insufficiency (Renal Failure) 11/2021 - 12/2002
2	Schizophrenia (Dementia Praecox) 01/2021 - 01/2020
2	Brain Injuries (Brain Injury) 01/2020 - 02/2010
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2020 - 01/2020
2	Cognitive Dysfunction 01/2020 - 01/2019
2	Skin Diseases (Skin Disease) 01/2020 - 01/2018
2	Epilepsy (Aura) 08/2018 - 01/2018
2	Leprosy (Hansen's Disease) 01/2016 - 05/2015
2	Meningitis 08/2015 - 03/2013
2	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 08/2015 - 10/2011
2	Human Influenza (Influenza) 01/2013 - 05/2007
2	Communicable Diseases (Infectious Diseases) 11/2012 - 12/2003
2	Lymphoma (Lymphomas) 06/2012 - 02/2003
2	Peritoneal Fibrosis 05/2012 - 07/2009
2	Atherosclerosis 10/2011 - 02/2010
2	Choroidal Neovascularization 10/2010 - 02/2007
2	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 01/2008 - 12/2006
2	Blister (Bulla) 05/2006 - 10/2005
2	Reperfusion Injury 09/2004 - 09/2003
2	Albuminuria 02/2004 - 12/2002
2	Nephritis 02/2004 - 09/2003
1	Mental Disorders (Mental Disorder) 01/2022
1	Barrett Esophagus (Barrett's Esophagus) 01/2022
1	Adenocarcinoma 01/2022

Drug/Important Bio-Agent (IBA)

106	Complement System Proteins (Complement)IBA 05/2022 - 01/2002
19	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2022 - 01/2002
18	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2003
13	Biomarkers (Surrogate Marker)IBA 06/2021 - 01/2017
13	Complement Factor H (Factor H)IBA 01/2020 - 10/2005
9	AntibodiesIBA 01/2021 - 01/2002
6	Complement Inactivating AgentsIBA 01/2022 - 02/2002
6	Complement Factor B (Factor B)IBA 01/2019 - 01/2007
5	Monoclonal AntibodiesIBA 01/2020 - 02/2003
4	CytokinesIBA 01/2021 - 12/2003
4	Amyloid (Amyloid Fibrils)IBA 01/2020 - 03/2009
4	AutoantibodiesIBA 01/2018 - 02/2004
4	Cholinergic ReceptorsIBA 08/2012 - 09/2007
4	CD55 Antigens (Decay Accelerating Factor)IBA 09/2005 - 02/2004
3	Complement C3b (C3bi)IBA 01/2022 - 01/2012
3	Complement C3 (C3 Complement)IBA 01/2022 - 10/2011
3	AntigensIBA 01/2020 - 05/2009
3	Complement C5 (Complement 5)IBA 01/2020 - 10/2011
3	Complement Receptors (Complement Receptor)IBA 01/2019 - 10/2002
3	anticomplementIBA 11/2015 - 10/2002
3	Complement C3-C5 Convertases (C3 Convertase)IBA 05/2014 - 01/2011
3	Immunoglobulin G (IgG)IBA 11/2010 - 02/2004
3	Peptides (Polypeptides)IBA 06/2010 - 07/2008
2	Messenger RNA (mRNA)IBA 01/2022 - 03/2004
2	Antigen-Antibody Complex (Immune Complex)IBA 11/2021 - 09/2003
2	Retinaldehyde (Retinal)IBA 12/2020 - 09/2010
2	Blood Proteins (Serum Proteins)IBA 01/2020 - 11/2019
2	eculizumab FDA Link 01/2020 - 10/2019
2	Complement C4 (Complement Component 4)IBA 01/2020 - 01/2009
2	C-Reactive ProteinIBA 01/2019 - 11/2008
2	Anaphylatoxin C5a ReceptorIBA 01/2018 - 10/2011
2	ClusterinIBA 01/2017 - 05/2014
2	ParaffinIBA 01/2016 - 03/2004
2	InflammasomesIBA 08/2013 - 07/2013
2	VenomsIBA 07/2012 - 07/2004
2	ZymosanIBA 05/2012 - 07/2009
2	ApolipoproteinsIBA 10/2011 - 02/2010
2	Transcription Factors (Transcription Factor)IBA 06/2010 - 05/2010
2	muskIBA 07/2008 - 01/2008
2	Indicators and Reagents (Reagents)IBA 03/2004 - 09/2003
2	CreatinineIBA 02/2004 - 09/2003
1	VaccinesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022

Therapy/Procedure

18	Therapeutics 01/2021 - 09/2003
4	Immunotherapy 12/2011 - 07/2008
3	Peritoneal Dialysis 01/2017 - 07/2009
2	Drug Therapy (Chemotherapy) 01/2021 - 02/2006
2	Lasers (Laser) 10/2010 - 02/2007